Inspire Medical Systems (NYSE:INSP) Announces Quarterly Earnings Results

Inspire Medical Systems (NYSE:INSP) issued its quarterly earnings results on Monday. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.33, Zacks reports. The business had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Inspire Medical Systems’s revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) EPS. Inspire Medical Systems updated its FY 2025 guidance to 2.200-2.300 EPS.

Inspire Medical Systems Trading Down 0.1 %

Shares of NYSE INSP opened at $159.67 on Tuesday. The stock has a fifty day simple moving average of $159.91 and a 200-day simple moving average of $179.25. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $256.11. The stock has a market capitalization of $4.75 billion, a PE ratio of 92.29, a PEG ratio of 2.86 and a beta of 1.39.

Insider Buying and Selling at Inspire Medical Systems

In other news, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. This trade represents a 77.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO John Rondoni sold 583 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,527 shares of company stock valued at $4,851,660 in the last three months. 4.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on INSP shares. Stifel Nicolaus lowered their price objective on Inspire Medical Systems from $190.00 to $175.00 and set a “hold” rating on the stock in a research report on Monday, April 21st. KeyCorp decreased their price objective on Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating on the stock in a report on Monday, April 21st. Piper Sandler decreased their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Robert W. Baird lowered their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 11th. Finally, Wells Fargo & Company decreased their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Inspire Medical Systems has an average rating of “Moderate Buy” and a consensus target price of $218.90.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.